The Price to Cash Flow for Europlasma S.A. (ENXTPA:ALEUP) is -1.894950. The price to cash flow formula is a useful tool investors can use in order to determine the value of a company. Generally, a higher P/CF ratio indicates that the company is less capital demanding and the lesser price to cash flow indicates that the company is more capital demanding.

Formula: Price to Cash Flow = Current Stock Price/ Cash Flow per Share

This ratio is calculated by dividing the market value of a company by cash from operating activities. Additionally, the price to earnings ratio is another popular way for analysts and investors to determine a company’s profitability. The price to earnings ratio for Europlasma S.A. (ENXTPA:ALEUP) is -1.110034. This ratio is found by taking the current share price and dividing by earnings per share.

Further, Price to Book ratio for Europlasma S.A. ENXTPA:ALEUP is -2.320305. A lower price to book ratio indicates that the stock might be undervalued.

Managing the stock portfolio can be a very challenging task. To manage the portfolio successfully, it can take a lot of dedicated time, effort, and perseverance. Studying the market and being in tune with the economic landscape can help investors gain the knowledge that is needed to come out on top. Controlling emotions and consistently following a plan may be the keys to keep the investor on track. As many seasoned investors know, the stock market can be a wild ride full of many ups and downs. Being able to stay calm and focused during the rocky periods can assist the investor when making those highly important portfolio decisions.

In taking a look at some additional key numbers, Europlasma S.A. (ENXTPA:ALEUP) has a current ERP5 Rank of 17244. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of Europlasma S.A. (ENXTPA:ALEUP) is 50.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.

Europlasma S.A. (ENXTPA:ALEUP) currently has a Montier C-score of 4.00000. This indicator was developed by James Montier in an attempt to identify firms that were fixing the books in order to appear better on paper. The score ranges from zero to six where a 0 would indicate no evidence of book cooking, and a 6 would indicate a high likelihood. A C-score of -1 would indicate that there is not enough information available to calculate the score. Montier used six inputs in the calculation. These inputs included a growing difference between net income and cash flow from operations, increasing receivable days, growing day’s sales of inventory, increasing other current assets, decrease in depreciation relative to gross property plant and equipment, and high total asset growth.

Europlasma S.A. (ENXTPA:ALEUP) has an M-score Beneish of -2.785938. This M-score model was developed by Messod Beneish in order to detect manipulation of financial statements. The score uses a combination of eight different variables. The specifics of the variables and formula can be found in the Beneish paper “The Detection of Earnings Manipulation”.

The Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of Europlasma S.A. (ENXTPA:ALEUP) is 96. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of Europlasma S.A. (ENXTPA:ALEUP) is 97.

At the time of writing, Europlasma S.A. (ENXTPA:ALEUP) has a Piotroski F-Score of 3. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

**Valuation**

Europlasma S.A. (ENXTPA:ALEUP) presently has a current ratio of 0.41. The current ratio, also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the current liabilities. The ratio is simply calculated by dividing current liabilities by current assets. The ratio may be used to provide an idea of the ability of a certain company to pay back its liabilities with assets. Typically, the higher the current ratio the better, as the company may be more capable of paying back its obligations.

The Earnings to Price yield of Europlasma S.A. ENXTPA:ALEUP is -0.900873. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one of the most popular methods investors use to evaluate a company’s financial performance. Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company. The Earnings Yield for Europlasma S.A. ENXTPA:ALEUP is -0.167474. Earnings Yield helps investors measure the return on investment for a given company. Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value. The Earnings Yield Five Year average for Europlasma S.A. (ENXTPA:ALEUP) is -0.207349.

Free Cash Flow Growth (FCF Growth) is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow. The FCF Growth of Europlasma S.A. (ENXTPA:ALEUP) is 0.429593. Free cash flow (FCF) is the cash produced by the company minus capital expenditure. This cash is what a company uses to meet its financial obligations, such as making payments on debt or to pay out dividends. The Free Cash Flow Score (FCF Score) is a helpful tool in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow. The FCF Score of Europlasma S.A. (ENXTPA:ALEUP) is 1.067375. Experts say the higher the value, the better, as it means that the free cash flow is high, or the variability of free cash flow is low or both.

**Volatility**

Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Europlasma S.A. (ENXTPA:ALEUP) is 85.732100. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Europlasma S.A. (ENXTPA:ALEUP) is 116.567900. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 87.980900.

Dedicated investors often strive hard to set themselves up for success. Finding long-lasting success in the stock market may not be an easy endeavor. The mindset of a short-term trader may differ greatly from that of a long-term investor. Investors often have to be prepared for many different situations. Obtaining the proper knowledge about stocks and the investing world is typically a main goal for active traders and investors. Once the investor is armed with knowledge, they may be able to see things that others cannot. This may involve staying up to date on various fundamentals, technicals, and macro-economic conditions.

Here we will take a look into some valuation metrics for Antisense Therapeutics Limited ASX:ANP shares.

**Price-To-Cash-Flow-Ratio** is a term that indicates the degree of cash flow valuation of the enterprise in the securities market. It is derived from the P/E – Price Earnings Ratio, in which the profit is replaced by cash flow. Unlike P/E, the ratio isn’t affected by the chosen depreciation methods, making it suitable for geographic comparison. Antisense Therapeutics Limited currently has a P/CF ratio of -5.165855.

New investors may be looking at the soaring stock market and wondering if now is a good time to try and get in on the action. Leaping into the market without proper research or a solid plan may leave the investor on the short end of the stick. Creating a stock investing plan can be as simple or complex as the individual chooses. Sometimes, keeping things simple may be the best way to go. Other times, there may be more than meets the eye, and a deep-dive into the crucial data may be required. New investors may be extremely excited to start buying stocks. They may have heard some great water cooler talk about the next big stock. There is always a possibility that the hot stock chatter may end up coming to fruition, but it could just as likely turn out to be terribly erroneous. Many individuals in the financial world will be quick to provide these can’t lose picks, but until this information is thoroughly researched, investors may want to proceed with caution.

**Volatility**

Watching some historical volatility numbers on shares of Antisense Therapeutics Limited (ASX:ANP), we can see that the 12 month volatility is presently 136.731900. The 6 month volatility is 207.184500, and the 3 month is spotted at 286.660500. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.

We can now take a quick look at some historical stock price index data. Antisense Therapeutics Limited (ASX:ANP) presently has a 10 month price index of 0.88889. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 1.06667, the 24 month is 0.88889, and the 36 month is 0.45714. Narrowing in a bit closer, the 5 month price index is 1.28000, the 3 month is 1.52381, and the 1 month is currently 0.82051.

**Valuation Ratios**

Looking at some ROIC (Return on Invested Capital) numbers, Antisense Therapeutics Limited (ASX:ANP)’s ROIC is -1.000000. The ROIC 5 year average is -3.072845 and the ROIC Quality ratio is -1.165077. ROIC is a profitability ratio that measures the return that an investment generates for those providing capital. ROIC helps show how efficient a firm is at turning capital into profits. In terms of EBITDA Yield, Antisense Therapeutics Limited (ASX:ANP) currently has a value of -0.231767. This value is derived by dividing EBITDA by Enterprise Value.

The Price to Book ratio (Current share price / Book value per share) is a good valuation measure you can use to find undervalued investment ideas. A low Price to Book could indicate that the shares are undervalued in their industry. Generally speaking a P/B ratio under 1 is considered low and is best used in relation to asset-heavy firms. At the time of writing Antisense Therapeutics Limited (ASX:ANP) has a price to book ratio of 2.817294.

The Leverage Ratio of Antisense Therapeutics Limited (ASX:ANP) is 0.000000. Leverage ratio is the total debt of a company divided by total assets of the current and past year divided by two. Companies take on debt to finance their day to day operations. The leverage ratio can measure how much of a company’s capital comes from debt. With this ratio, investors can better estimate how well a company will be able to pay their long and short term financial obligations.

Stock market investors often rely on fundamental analysis for stock research. The EPS or earnings per share ratio shows the amount of company earnings that can be attributed to every share that is held. EPS lets investors directly compare one company to another when examining potential investments. Investors are typically searching for stocks that have a growing EPS. The EPS measure tends to be more telling when viewed over a longer period of time. When companies report quarterly earnings, the EPS measure is highly scrutinized by investors and analysts alike.

There are many different tools to determine whether a company is profitable or not. One of the most popular ratios is the “Return on Assets” (aka ROA). This score indicates how profitable a company is relative to its total assets. The Return on Assets for Antisense Therapeutics Limited (ASX:ANP) is -0.918078. This number is calculated by dividing net income after tax by the company’s total assets. A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return.

The Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of Antisense Therapeutics Limited (ASX:ANP) is 93. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of Antisense Therapeutics Limited (ASX:ANP) is 97.

Stock market investors often rely on fundamental analysis for stock research. The EPS or earnings per share ratio shows the amount of company earnings that can be attributed to every share that is held. EPS lets investors directly compare one company to another when examining potential investments. Investors are typically searching for stocks that have a growing EPS. The EPS measure tends to be more telling when viewed over a longer period of time. When companies report quarterly earnings, the EPS measure is highly scrutinized by investors and analysts alike.

At the time of writing, Antisense Therapeutics Limited (ASX:ANP) has a Piotroski F-Score of 4. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

The Price to book ratio is the current share price of a company divided by the book value per share. The Price to Book ratio for Antisense Therapeutics Limited ASX:ANP is 2.817294. A lower price to book ratio indicates that the stock might be undervalued. Similarly, Price to cash flow ratio is another helpful ratio in determining a company’s value. The Price to Cash Flow for Antisense Therapeutics Limited (ASX:ANP) is -5.165855. This ratio is calculated by dividing the market value of a company by cash from operating activities. Additionally, the price to earnings ratio is another popular way for analysts and investors to determine a company’s profitability. The price to earnings ratio for Antisense Therapeutics Limited (ASX:ANP) is -5.101587. This ratio is found by taking the current share price and dividing by earnings per share.

There are many factors that can affect the health of a company. This is one reason why stock trading can be extremely difficult at times. Because there are always so many things to take into consideration, it may be next to impossible to create a formula that will continually beat the market. Even after all the data has been scrutinized and the numbers have been crunched, the investor still has to make sense of the information and figure out what to do with it. Knowing how to use the information about publically traded companies can end up being the difference between handsome gains and devastating losses.

**Receive News & Ratings Via Email** - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.